Pet Pharm Biotech Co Ltd

Pet Pharm Biotech Co Ltd maintains a strong liquidity position with a current ratio of 10.68, indicating a high ability to meet short-term obligations. However, the company's cash and equivalents amount to only TWD 109,000, which is significantly lower than its long-term debt of TWD 106,159,000, suggesting a potential liquidity risk. The company's profitability is modest, with a return on equity of 2.13% and a return on assets of 1.85%. These figures are below the industry median for pharmaceutical companies, indicating that the company is not generating returns as efficiently as its peers. Geographically, the company's revenue is concentrated in Taiwan, with no significant international revenue streams disclosed. This concentration increases the company's exposure to local economic and regulatory changes, which could impact its revenue stability. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical revenue data shows a revenue of TWD 222,032,000, but without a clear trend or outlook, it is difficult to assess the company's future performance. The company faces moderate liquidity risk, as noted in the risk assessment, and has a low dilution risk. However, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near future, which could lead to dilution. Recent events, such as analyst estimates, indicate a mixed outlook. The mean recommendation is 2.00, with one "buy" rating and no "strong buy" or "sell" ratings. The last actual EPS was TWD 0.46, and the last actual revenue was TWD 222,032,000, which provides a baseline for future performance comparisons.